B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia

KOČKOVÁ, Helena, Karla PLEVOVÁ, Jitka MALČÍKOVÁ, Jana KOTAŠKOVÁ, Vojtěch BYSTRÝ, Veronika MANČÍKOVÁ, Martin TRBUŠEK, Michaela HLOŽKOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK and Šárka POSPÍŠILOVÁ. B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia. In CEITEC PHD RETREAT II. 2017.

Basic information

• Original name: B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia
• Authors: KOČKOVÁ, Helena (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Michaela HLOŽKOVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution).
• Edition: CEITEC PHD RETREAT II, 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 10606 Microbiology
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14740/17:00096943
• Organization unit: Central European Institute of Technology
• Keywords in English: CLL; receptor; genomic defects
• Tags: rivok

Abstract

B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia, B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1106/2016, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

• NV15-31834A, research and development project: Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie